Licarin A |
| Catalog No.GC60225 |
Licarin A ((+)-Licarin A), a neolignan, significantly and dose-dependently reduces TNF-α production (IC50=12.6 μM) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 51020-86-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Licarin A ((+)-Licarin A), a neolignan isolated from various plants, significantly and dose-dependently reduces TNF-α production (IC50=12.6±0.3 μM) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects. Licarin A reduces TNF-α and PGD2 production, and COX-2 expression[1].
Licarin A is found in plants such as Aristolochia taliscana, Machilus thunbergii and Myristica fragrans, which are used as spices and in folk medicines for nervous and digestive disorders. Licarin A also exhibits anti-inflammatory effects[1]. Licarin A (5-20 μM) reduces TNF-α and prostaglandin D2 (PGD2) secretion via the inhibition of PKCα/βII and p38 MAPK pathways. Licarin A treatment tends to reduce phosphorylated PKCα/βII and p38 MAPK protein levels[1].
[1]. Takuya Matsui, et al. Licarin A Is a Candidate Compound for the Treatment of Immediate Hypersensitivity via Inhibition of Rat Mast Cell Line RBL-2H3 Cells. J Pharm Pharmacol. 2015 Dec;67(12):1723-32.
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *